Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India

[1]  J. Dalal,et al.  Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population , 2022, Cardiology and Therapy.

[2]  C. Ponde,et al.  Fondaparinux: A cornerstone drug in acute coronary syndromes , 2022, World journal of cardiology.

[3]  Deepak L. Bhatt,et al.  2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2021, Circulation.

[4]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[5]  G. Hindricks,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. , 2017, Revista espanola de cardiologia.

[6]  A. Zaman,et al.  Anticoagulant Therapy for Acute Coronary Syndromes. , 2017, Interventional cardiology.

[7]  S. Inglis,et al.  Education and practice gaps on atrial fibrillation and anticoagulation: a survey of cardiovascular nurses , 2016, BMC medical education.

[8]  J. Carrero,et al.  Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. , 2015, JAMA.

[9]  E. Aliot,et al.  SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: a pilot study. , 2015, Archives of cardiovascular diseases.

[10]  T. Nair,et al.  A multicentre retrospective study to understand anti-platelet treatment patterns and outcomes of acute coronary syndrome patients in India (TRACE). , 2014, Indian heart journal.

[11]  M. Humphreys.  Non‐ST Segment Elevation Myocardial Infarction , 2013 .

[12]  R. de Caterina,et al.  Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) , 2013, Thrombosis and Haemostasis.

[13]  Mark D. Huffman,et al.  Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. , 2013, European heart journal.

[14]  E. Bates,et al.  Acute ST-elevation myocardial infarction , 2012, Current opinion in critical care.

[15]  U. Kaul,et al.  Approach to STEMI and NSTEMI. , 2011, The Journal of the Association of Physicians of India.

[16]  S. Yusuf,et al.  Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study , 2011, Journal of Thrombosis and Thrombolysis.

[17]  S. Yusuf,et al.  Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial , 2010, The Lancet.

[18]  M. Oertel,et al.  Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues , 2009, The Annals of pharmacotherapy.

[19]  S. Yusuf,et al.  Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data , 2008, The Lancet.

[20]  Salim Yusuf,et al.  The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. , 2008, European heart journal.

[21]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[22]  S. Yusuf,et al.  Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. , 2007, Journal of the American College of Cardiology.

[23]  H. White,et al.  Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. , 2007, Journal of the American College of Cardiology.

[24]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[25]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[26]  J. Thakur,et al.  Urbanization and coronary heart disease: a study of urban-rural differences in northern India. , 2006, Indian heart journal.

[27]  J. Ferguson.  Clopidogrel plus aspirin in patients with acute myocardial infarction treated with fibrinolytic therapy--CLARITY-TIMI 28. , 2005, Future cardiology.

[28]  J. Mehilli,et al.  [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. , 2016, Giornale italiano di cardiologia.

[29]  K. Mahaffey,et al.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .

[30]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[31]  K. Fox.  Management of acute coronary syndromes: an update , 2004, Heart.